CorMedix (CRMD) Misses Q4 EPS by 69c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts CRMD Hot Sheet
Join SI Premium – FREE
CorMedix (NASDAQ: CRMD) reported Q4 EPS of $0.16, $0.69 worse than the analyst estimate of $0.85. Revenue for the quarter came in at $128.6 million versus the consensus estimate of $128.48 million.
For earnings history and earnings-related data on CorMedix (CRMD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- AMTD Digital reports $1.2B in total assets, $42.4M profit
- FDA approves first once-weekly insulin for type 2 diabetes mellitus in pediatric patients
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
